WHO Guidelines Set New Standard for GLP-1 Obesi...

By HEOR Staff Writer

December 4, 2025

What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 du...
Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Res...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line The...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Comb...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Weight Loss: Advances in Hormone-Based Obesity Treatments
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Rece...